TrialHeart and vessels2018

Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.

Atsushi Tanaka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.